earnings-product-pipeline — Claude Code skill: product pipeline
earnings-product-pipeline extracts product development data from earnings calls: clinical trial status, regulatory submissions, launch timelines.
MIT 265 installs ★ 132 updated 2026-06-05
npx skills add OctagonAI/skills --skill earnings-product-pipeline -a claude-codeWhat earnings-product-pipeline does
The skill parses earnings call transcripts and collects product pipeline information. Looks for trial phases (Phase 1, Phase 2, Phase 3), regulatory filings (IND, NDA, BLA), launch dates, and R&D investments. Returns a structured table with key milestones, timelines, trial status, and transcript page references.
Requires Octagon MCP configured — queries fail without it. Supports filtering by data type: you can request only regulatory updates or only launch timelines. Generates follow-up questions for deeper analysis and builds a catalyst calendar with risk assessment for each event.
Query examples: Extract product development and pipeline updates from MRNA's latest earnings call discussion, What regulatory submissions or approvals were discussed in PFE's call?, Extract clinical trial updates from JNJ's earnings transcript.
What it helps with
- extract clinical trial data from earnings calls
- collect a company's regulatory submission timeline
- track product pipeline progress through transcripts
- build a catalyst calendar with Phase 3 data dates
- find R&D priorities in earnings reports
Example prompts for the agent
- Extract product pipeline updates from
MRNA's latest earnings call - What regulatory submissions were discussed in
PFE's earnings call? - Collect clinical trial information from
JNJ's earnings transcript
How to install earnings-product-pipeline
1Skills CLI (Vercel)
npx skills add OctagonAI/skills --skill earnings-product-pipeline -a claude-code2Manually: put the files in place
~/.claude/skills/earnings-product-pipeline/SKILL.mdCopy the whole skill folder; for one project use .claude/skills/earnings-product-pipeline/
1Skills CLI (Vercel)
npx skills add OctagonAI/skills --skill earnings-product-pipeline -a codex2Manually: put the files in place
.agents/skills/earnings-product-pipeline/SKILL.mdFor all projects use ~/.agents/skills/
1Skills CLI (Vercel)
npx skills add OctagonAI/skills --skill earnings-product-pipeline -a cursor2Manually: put the files in place
.cursor/skills/earnings-product-pipeline/SKILL.mdCursor also reads .agents/skills/ and .claude/skills/
1GitHub CLI
gh skill install OctagonAI/skills skills/earnings-product-pipeline2Manually: put the files in place
.github/skills/earnings-product-pipeline/SKILL.md1Skills CLI (Vercel)
npx skills add OctagonAI/skills --skill earnings-product-pipeline -a gemini-cli2Platform CLI
gemini skills install https://github.com/OctagonAI/skills --path skills/earnings-product-pipelineManually: put the files in place
.devin/skills/earnings-product-pipeline/SKILL.mdThe legacy .windsurf/skills/ path still works
Skills CLI (Vercel)
npx skills add OctagonAI/skills --skill earnings-product-pipeline -a opencodeClaude.ai
Zip the folder and upload it in Settings → Capabilities → Skills
Step by step, with commands for each platform: How to install skills in Claude Code: five ways
Questions about earnings-product-pipeline
How to install earnings-product-pipeline in Claude Code?
Run npx skills add OctagonAI/skills --skill earnings-product-pipeline -a claude-code, then open ~/.claude/skills/earnings-product-pipeline/SKILL.md.
What does earnings-product-pipeline do?
Pulls product development data from earnings calls: trial status, regulatory submissions, launch timelines. Returns a structured table with dates and transcript page references.
What does earnings-product-pipeline require?
Octagon MCP configured. Without it, the skill cannot query earnings calls.
Source text
SKILL.md · MIT
--- name: earnings-product-pipeline description: Extract product development and pipeline updates from earnings calls, including clinical trial progress, regulatory submissions, and launch timelines. --- # Earnings Product Pipeline Extract product development and pipeline updates from earnings call transcripts, including R&D milestones, clinical trial progress, regulatory submissions, and product launch timelines. ## Prerequisites Ensure Octagon MCP is configured. See [references/mcp-setup.md](references/mcp-setup.md) for installation instructions. ## Workflow ### Step 1: Extract Pipeline Updates Use the Octagon MCP to analyze product pipeline discussions: ``` Extract product development and pipeline updates from <TICKER>'s latest earnings call discussion. ``` ### Step 2: Targeted Pipeline Analysis Focus on specific aspects of product development: ``` # Full Pipeline What product pipeline updates were discussed in <TICKER>'s earnings call? # Clinical Trials Extract clinical trial updates from <TICKER>'s earnings transcript. # Regulatory Progress What regulatory submissions or approvals were discussed in <TICKER>'s call? # Launch Timeline Extract product launch timelines from <TICKER>'s earnings call. # R&D Investments What R&D priorities were highlighted in <TICKER>'s earnings transcript? # Stage Progression Which products advanced to new stages in <TICKER>'s pipeline? ``` ## Expected Output The skill returns structured pipeline analysis including: | Component | Description | |-----------|-------------| | Development Milestones | Key progress updates | | Clinical Trials | Trial status and data timelines | | Regulatory Submissions | FDA/EMA filings and approvals | | Launch Timeline | Expected commercialization dates | | Portfolio Overview | Stage-by-stage breakdown | | Follow-up Questions | AI-generated questions for deeper research | | Source Citations | Transcript page references | ## Example Query ``` Extract product development and pipeline updates from MRNA's latest earnings call discussion. ``` ## Example Response **Moderna, Inc. (MRNA) Product Development and Pipeline Updates (Q4 2024)** Moderna highlighted key product development and pipeline updates in their earnings call: **Product Development Milestones** - **Methylmalonic Acidemia (MMA) Test Products**: Achieving critical milestones with three regulatory submissions filed - **CMV Vaccine**: Anticipating final Phase 3 results in 2025 - **Flu and Norovirus Vaccines**: Both in Phase 3 trials, with data timelines contingent on case accrual - **INT Adjuvant Melanoma**: Progress dependent on patient accrual - **PA (Pneumonia) Vaccine**: Awaiting data from a registrational study, with plans to initiate a new MMA registrational study within the year **Portfolio Overview** - Approved Products: 2 - Advanced-Stage Candidates: 3 - Phase 3/Pivotal Studies: 6 ongoing The updates underscore Moderna's expanding mRNA platform pipeline. **Follow-up Questions** - What are the specific regulatory submissions for MMA test products? - What are the enrollment targets for the flu and norovirus Phase 3 trials? - What are the primary endpoints for the INT adjuvant melanoma study? **Source**: MRNA_Q42024, Page: 4 ## Pipeline Stage Framework ### Development Stages | Stage | Description | Probability of Success | |-------|-------------|------------------------| | Discovery | Early research | 5-10% | | Preclinical | Lab/animal studies | 10-15% | | Phase 1 | Safety, dosing | 15-25% | | Phase 2 | Efficacy signal | 25-40% | | Phase 3 | Pivotal trials | 50-70% | | Regulatory | Under review | 85-95% | | Approved | Marketed | 100% | ### Pipeline Progression Signals | Signal | Interpretation | |--------|----------------| | "Initiated Phase X" | Moving forward | | "Positive interim data" | Encouraging results | | "Met primary endpoint" | Success, advancing | | "Did not meet endpoint" | Failure, reassess | | "Regulatory submission" | Final stages | | "FDA priority review" | Accelerated timeline | ## Clinical Trial Analysis ### Trial Status Categories | Status | Description | Next Milestone | |--------|-------------|----------------| | Enrolling | Recruiting patients | Full enrollment | | Fully Enrolled | Recruitment complete | Data readout | | Ongoing | Treatment/observation | Primary endpoint | | Data Collection | Gathering results | Analysis | | Readout Expected | Results imminent | Announcement | ### Trial Data Timeline | Trial Phase | Typical Duration | Data Timing | |-------------|------------------|-------------| | Phase 1 | 1-2 years | End of phase | | Phase 2 | 2-3 years | Interim + final | | Phase 3 | 2-4 years | Interim + final | | Regulatory | 6-12 months | Approval decision | ## Regulatory Progress Tracking ### Submission Types | Type | Description | Timeline | |------|-------------|----------| | IND | Investigational New Drug | Pre-Phase 1 | | NDA | New Drug Application | Post-Phase 3 | | BLA | Biologics License Application | Post-Phase 3 | | sNDA | Supplemental NDA | Line extension | | EUA | Emergency Use Authorization | Expedited | ### Regulatory Milestones | Milestone | Significance | |-----------|--------------| | IND Clearance | Can begin human trials | | Fast Track | Expedited review pathway | | Breakthrough | Intensive FDA guidance | | Priority Review | 6-month review | | Standard Review | 10-12 month review | | PDUFA Date | Decision deadline | | Approval | Can commercialize | ## Portfolio Summary Analysis ### Pipeline Inventory | Stage | Count | Key Programs | |-------|-------|--------------| | Approved | 2 | COVID vaccine, RSV | | Phase 3 | 6 | CMV, Flu, Norovirus | | Phase 2 | 8 | Oncology programs | | Phase 1 | 10 | Early candidates | | Preclinical | 15+ | Discovery programs | ### Portfolio Value Framework ``` Pipeline Valuation Approach: Approved Products: - Revenue projection × multiple Phase 3 Candidates: - Peak sales potential × probability (60%) Phase 2 Candidates: - Peak sales potential × probability (30%) Phase 1 Candidates: - Option value × probability (15%) Total Pipeline Value: Sum of risk-adjusted values ``` ## Catalyst Calendar ### Building a Catalyst Tracker | Catalyst | Product | Timeline | Impact | |----------|---------|----------|--------| | Phase 3 Data | CMV Vaccine | 2025 | High | | FDA Decision | Product X | Q2 2025 | Very High | | Phase 2 Interim | Oncology | Q3 2025 | Medium | | IND Filing | New Program | Q4 2025 | Low | ### Catalyst Risk Assessment | Factor | Lower Risk | Higher Risk | |--------|------------|-------------| | Phase | Later stage | Earlier stage | | Endpoint | Objective | Subjective | | Trial Size | Large | Small | | Prior Data | Positive | Mixed | | Competition | Limited | Crowded | ## Sector-Specific Considerations ### Biotech/Pharma | Focus Area | Key Metrics | |------------|-------------| | Clinical Data | Efficacy, safety | | Regulatory Path | FDA interactions | | Commercial | Market size, pricing | | Manufacturing | Capacity, supply | ### Technology | Focus Area | Key Metrics | |------------|-------------| | Product Launches | Timing, features | | Beta Programs | User feedback | | GA Release | Availability | | Feature Roadmap | Future capabilities | ### Consumer Products | Focus Area | Key Metrics | |------------|-------------| | New SKUs | Product variants | | Distribution | Retail expansion | | Marketing | Launch support | | Consumer Testing | Reception data | ## Use Cases 1. **Pipeline Valuation**: Assess portfolio value 2. **Catalyst Trading**: Track binary events 3. **Competitive Analysis**: Compare pipelines 4. **R&D Assessment**: Evaluate innovation 5. **Investment Thesis**: Validate growth drivers 6. **Risk Analysis**: Identify pipeline gaps ## Combining with Other Skills | Skill | Combined Analysis | |-------|-------------------| | earnings-capital-allocation | R&D investment vs. pipeline | | sec-10k-analysis | Full pipeline disclosure | | earnings-competitive-review | Pipeline vs. competitors | | analyst-estimates | Pipeline in consensus | | stock-price-change | Catalyst impact on price | ## Analysis Tips 1. **Track Timelines**: Note when data is expected 2. **Compare to Prior Quarters**: What advanced or slipped? 3. **Assess Probability**: Apply success rates by stage 4. **Watch for Delays**: Slipping timelines signal issues 5. **Competitor Context**: How does pipeline compare? 6. **Commercial Potential**: Estimate peak sales for key assets ## Interpreting Results See [references/interpreting-results.md](references/interpreting-results.md) for detailed guidance on analyzing product pipeline updates.
© OctagonAI · MIT · OctagonAI/skills